Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA ...

Scientists at the UCLA Health Jonsson Comprehensive Cancer Center and the University of Toronto have revealed how a tiny ...

Scientists have revealed how a tiny chemical modification in RNA, known as m6A, plays a critical role in the progression of ...

Researchers focused on Myotonic Dystrophy 1 heart problems are testing a novel approach to restore normal function.

Accumulation of a protein called TDP-43 is a key feature of ALS and frontotemporal dementia. In a study published in Neuron, ...

Researchers have developed a laboratory model that mimics the pathological aggregation of TDP-43, a key protein in ALS and ...

Accumulation of a protein called TDP-43 is a key feature of ALS and frontotemporal dementia. In a newly published study, ...

Scientists at the UCLA Health Jonsson Comprehensive Cancer Center and the University of Toronto have revealed how a tiny chemical modification in RNA, known as m6A, plays a critical role in the ...

Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules ...

Scientists at Oak Ridge National Laboratory have developed the first-ever method of detecting ribonucleic acid, or RNA, ...